The Specialty Care business unit of Sanofi focuses on developing therapies for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.
With over 40 years working alongside the rare disease community, Sanofi is grounded in both the science behind these conditions and the experiences of the people who face them. We proudly maintain one of the largest rare disease pipelines in the industry across multiple disease modalities. In the U.S., we currently have approved products for patients with Fabry disease, Gaucher disease type 1, MPS disease type 1, Pompe disease and Acid sphingomyelinase deficiency (ASMD). We pledge to work toward equitable access to rare disease medicines; develop new and innovative therapies; strive to eliminate the long search for diagnosis; and elevate the voices of the rare disease community.
Rare Blood Disorders
We strive to significantly improve the health and lives of people with rare blood disorders around the world with groundbreaking science. We have a strong legacy of innovation in rare diseases, decades of expertise in hematology, and a steadfast commitment to the community. In the U.S., we have approved first-in-class therapies for patients with hemophilia A and B, as well as acquired thrombotic thrombocytopenic purpura (aTTP), and cold agglutinin disease (CAD).
We are determined to help people living with neurological disorders through the development of innovative solutions and potential new treatments. We currently have two approved therapies for patients with relapsing multiple sclerosis, and our scientists are deploying an array of technologies to develop new potential treatments that may help address the underlying cause of disease. Additionally, Neurology is an area of continued focus on innovation with research in key areas including Myasthenia gravis, amyotrophic lateral sclerosis (ALS), multiple sclerosis, and other neurological diseases.
At Sanofi, we are dedicated to delivering the best cancer care that fits in the lives of people living with this disease. We’re pushing the boundaries of scientific innovation to make meaningful breakthroughs and expand access to our treatments. Together, with leaders and partners in the healthcare community, we’re working to address critical gaps in care and translate scientific discoveries into new treatment options and standards of care. Through our robust oncology pipeline across solid tumor and hematologic cancers, we’re harnessing the immune system with greater precision, investigating novel cancer compounds, and reaching new genetic targets, all to help improve outcomes and change the lives of people living with cancer. Click here to learn more about Sanofi Oncology
We have a first in class treatment and robust pipeline of potential new medicines for a variety of chronic inflammatory diseases. We currently have a marketed product with several indications in dermatology, respiratory and gastroenterology, and being evaluated for additional conditions, including ones with underlying type 2 inflammation. Another marketed product is currently indicated for rheumatological conditions, arthritis and polymyalgia rheumatica, and is also being evaluated for additional indications. Our robust pipeline in immunology has us exploring key areas in more than a dozen disease states.